National Cancer Institute; Notice of Closed Meetings, 53491-53492 [2018-23069]
Download as PDF
<![CDATA[
khammond on DSK30JT082PROD with NOTICES
Federal Register / Vol. 83, No. 205 / Tuesday, October 23, 2018 / Notices
Bethesda, MD 20892, 301–827–2864,
maskerib@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Biobehavioral Applications in
Ethology and Substance Abuse.
Date: November 15, 2018.
Time: 12:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Andrea B. Kelly, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3182,
MSC 7770, Bethesda, MD 20892, (301) 455–
1761, kellya2@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; AREA
Application Review.
Date: November 19, 2018.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Katherine M. Malinda,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4140,
MSC 7814, Bethesda, MD 20892, 301–435–
0912, Katherine_Malinda@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; AREA
Application Review.
Date: November 19, 2018.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Larry Pinkus, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4132,
MSC 7802, Bethesda, MD 20892, (301) 435–
1214, pinkusl@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research; 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: October 17, 2018.
David D. Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–2: NCI
Clinical and Translational R21 and Omnibus
R03.
Date: November 7, 2018.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W112, Rockville, MD 20850 (Telephone
Conference Call).
[FR Doc. 2018–23035 Filed 10–22–18; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
20:20 Oct 22, 2018
Jkt 247001
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases;
Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the Diabetes,
Endocrinology and Metabolic Diseases B
Subcommittee, October 24, 2018, 05:30
p.m. to October 26, 2018, 04:00 p.m.,
Residence Inn Capital View, 2850 South
Potomac Avenue, Arlington, VA, 22202
which was published in the Federal
Register on September 12, 2018, 64 FR
46178.
The meeting is being amended to
reflect location change. The new
meeting location is the Renaissance
Washington DC Downtown, 999 9th
Street NW, Washington, DC 20001. The
meeting is closed to the public.
Dated: October 17, 2018.
David D. Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–23033 Filed 10–22–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
53491
Contact Person: Jennifer C. Schiltz, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W112, Bethesda, MD
20892–9750, 240–276–5864, jennifer.schiltz@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Collaborative Human Tissue Network
(CHTN) (UM1).
Date: November 14, 2018.
Time: 10:30 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W122, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Sanita Bharti, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W122,
Bethesda, MD 20892–9750, 240–276–5909,
sanitab@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SBIR Phase
IIB Bridge Awards.
Date: November 15, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W114, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Jeffrey E. DeClue, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W114, Bethesda, MD 20892–
9750, 240–276–6371, decluej@mail.nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group Subcommittee
A—Cancer Centers.
Date: November 29, 2018.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Shamala K. Srinivas,
Ph.D., Scientific Review Officer, Office of
Referral, Review, and Program Coordination,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W530, Bethesda, MD 20892–
9750, 240–276–6442, ss537t@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Cancer
Center Support Grant (P30).
Date: November 29, 2018.
Time: 4:30 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Shamala K. Srinivas,
Ph.D., Scientific Review Officer, Office of
Referral, Review, and Program Coordination,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
E:\FR\FM\23OCN1.SGM
23OCN1
53492
Federal Register / Vol. 83, No. 205 / Tuesday, October 23, 2018 / Notices
Drive, Room 7W530, Bethesda, MD 20892–
9750, 240–276–6442, ss537t@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: October 17, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–23069 Filed 10–22–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Frederick National
Laboratory Advisory Committee to the
National Cancer Institute, October 29,
2018, 09:30 a.m. to October 29, 2018,
04:30 p.m., National Cancer Institute
Shady Grove, 9609 Medical Center
Drive, TE406, Rockville, MD, 20850
which was published in the Federal
Register on October 11, 2018, 83 FR
51468.
The meeting notice is amended to
change the start and end time of the
meeting from 9:30 a.m.–4:30 p.m. to
9:00 a.m.–4:00 p.m. on October 29,
2018. The meeting is open to the public.
Dated: October 17, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–23070 Filed 10–22–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
khammond on DSK30JT082PROD with NOTICES
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
VerDate Sep<11>2014
20:20 Oct 22, 2018
Jkt 247001
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: Community Mental
Health Services Block Grant and
Substance Abuse Prevention and
Treatment Block Grant FY 2020–2021
Plan and Report Guidance and
Instructions (OMB No. 0930–0168)—
Extension
The Substance Abuse and Mental
Health Services Administration
(SAMHSA) is requesting approval from
the Office of Management and Budget
(OMB) for an extension of the 2018–19
Community Mental Health Services
Block Grant (MHBG) and Substance
Abuse Prevention and Treatment Block
Grant (SABG) Plan and Report Guidance
and Instructions.
Currently, the SABG and the MHBG
differ on a number of their practices
(e.g., data collection at individual or
aggregate levels) and statutory
authorities (e.g., method of calculating
MOE, stakeholder input requirements
for planning, set asides for specific
populations or programs, etc.).
Historically, the Centers within
SAMHSA that administer these block
grants have had different approaches to
application requirements and reporting.
To compound this variation, states have
different structures for accepting,
planning, and accounting for the block
grants and the prevention set aside
within the SABG. As a result, how these
dollars are spent and what is known
about the services and clients that
receive these funds varies by block grant
and by state.
SAMHSA has conveyed that block
grant funds must be directed toward
four purposes: (1) To fund priority
treatment and support services for
individuals without insurance or who
cycle in and out of health insurance
coverage; (2) to fund those priority
treatment and support services not
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
covered by Medicaid, Medicare or
private insurance offered through the
exchanges and that demonstrate success
in improving outcomes and/or
supporting recovery; (3) to fund
universal, selective and targeted
prevention activities and services; and
(4) to collect performance and outcome
data to determine the ongoing
effectiveness of behavioral health
prevention, treatment and recovery
support services and to plan the
implementation of new services on a
nationwide basis.
To help states meet the challenges of
2020 and beyond, and to foster the
implementation and management of an
integrated physical health, mental
health and addiction service system,
SAMHSA has established standards and
expectations that will lead to an
improved system of care for individuals
with or at risk of mental and substance
use disorders. Therefore, this
application package continues to fully
exercise SAMHSA’s existing authority
regarding states’, territories’ and the Red
Lake Band of the Chippewa Tribe’s
(subsequently referred to as ‘‘states’’)
use of block grant funds as they fully
integrate behavioral health services into
the broader health care continuum.
Consistent with previous
applications, the FY 2020–2021
application has sections that are
required and other sections where
additional information is requested. The
FY 2020–2021 application requires
states to submit a face sheet, a table of
contents, a behavioral health assessment
and plan, reports of expenditures and
persons served, an executive summary,
and funding agreements and
certifications. In addition, SAMHSA is
requesting information on key areas that
are critical to the states success in
addressing health care integration.
Therefore, as part of this block grant
planning process, SAMHSA is asking
states to identify both their promising or
effective strategies as well as their
technical assistance needs to implement
the strategies they identify in their plans
for FYs 2020 and 2021.
To facilitate an efficient application
process for states, SAMHSA utilized the
questions and requests for clarification
from representatives from SMHAs and
SSAs to inform the proposed changes to
the block grants. Based on these
discussions with states, SAMHSA is
proposing de minimis changes to the
block grant program, consisting of
updated dates and clarification to
instructions.
While the statutory deadlines and
block grant award periods remain
unchanged, SAMHSA encourages states
to turn in their application as early as
E:\FR\FM\23OCN1.SGM
23OCN1
]]>Agencies
[Federal Register Volume 83, Number 205 (Tuesday, October 23, 2018)]
[Notices]
[Pages 53491-53492]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-23069]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; SEP-2: NCI Clinical and Translational R21 and Omnibus R03.
Date: November 7, 2018.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute, Shady Grove, 9609 Medical
Center Drive, Room 7W112, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Jennifer C. Schiltz, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W112, Bethesda, MD 20892-9750, 240-276-5864,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; Collaborative Human Tissue Network (CHTN) (UM1).
Date: November 14, 2018.
Time: 10:30 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute, Shady Grove, 9609 Medical
Center Drive, Room 7W122, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Sanita Bharti, Ph.D., Scientific Review Officer,
Research Program Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W122, Bethesda, MD 20892-9750, 240-276-5909, [email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; SBIR Phase IIB Bridge Awards.
Date: November 15, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute, Shady Grove, 9609 Medical
Center Drive, Room 7W114, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Jeffrey E. DeClue, Ph.D., Scientific Review
Officer, Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W114, Bethesda, MD 20892-9750, 240-276-6371,
[email protected].
Name of Committee: National Cancer Institute Initial Review
Group Subcommittee A--Cancer Centers.
Date: November 29, 2018.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites, 6711 Democracy Boulevard,
Bethesda, MD 20817.
Contact Person: Shamala K. Srinivas, Ph.D., Scientific Review
Officer, Office of Referral, Review, and Program Coordination,
Division of Extramural Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W530, Bethesda, MD 20892-9750, 240-
276-6442, [email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; Cancer Center Support Grant (P30).
Date: November 29, 2018.
Time: 4:30 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites, 6711 Democracy Boulevard,
Bethesda, MD 20817 (Telephone Conference Call).
Contact Person: Shamala K. Srinivas, Ph.D., Scientific Review
Officer, Office of Referral, Review, and Program Coordination,
Division of Extramural Activities, National Cancer Institute, NIH,
9609 Medical Center
[[Page 53492]]
Drive, Room 7W530, Bethesda, MD 20892-9750, 240-276-6442,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: October 17, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-23069 Filed 10-22-18; 8:45 am]
BILLING CODE 4140-01-P
